Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 19/20 | 1.00 |
| ▸ | PRKCA | P17252 | 3/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.56 |
| ▸ | PRKCG | P05129 | 1/20 | 0.56 |
| ▸ | PRKCB | P05771 | 1/20 | 0.56 |
| ▸ | PRKCH | P24723 | 1/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.56 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489909 | 1.00 | TOP1 (1.00) | TOP1PRKCAEGFRPRKD3PRKCG | |
| SCHEMBL14498681 | 0.93 | TOP1 (1.00) | TOP1PRKCAEGFR | |
| SCHEMBL7022916 | 0.93 | TOP1 (1.00) | TOP1PRKCAEGFR | |
| SCHEMBL5664777 | 0.93 | TOP1 (1.00) | TOP1PRKCAEGFR | |
| SCHEMBL3969257 | 0.91 | TOP1 (1.00) | TOP1PRKCAEGFRPRKD3PRKCG | |
| SCHEMBL6739046 | 0.88 | TOP1 (0.87) | TOP1PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL29489888 | 0.88 | TOP1 (0.87) | TOP1PRKCAPRKD3PRKCGPRKCB | |
| SCHEMBL6741558 | 0.87 | TOP1 (0.77) | TOP1PRKCAEGFRPRKD3PRKCG | |
| SCHEMBL7855047 | 0.87 | TOP1 (0.87) | TOP1PRKCAEGFRPRKD3PRKCG | |
| SCHEMBL5667987 | 0.86 | TOP1 (1.00) | TOP1PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686385-B2 | USEFUL IN INHIBITING THE PROLIFERATION OF TUMOR CELLS | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-6677450-B2 | N12, N13-BRIDGED SUGAR DERIVATIVES OF INDOLYLOPYRROLOCARBAZOLES, USEFUL IN INHIBITING THE PROLIFERATION OF TUMOR CELLS | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030220387-A1 | ANHYDRO SUGAR DERIVATIVES OF INDOLOCARBAZOLES | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-27 | — | — | US | disclosed |
| US-6610727-B2 | Antitumor agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| EP-1326874-A2 | TOPOISOMERASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326876-A2 | ANHYDRO SUGAR DERIVATIVES OF INDOLOCARBAZOLES | Bristol-Myers Squibb Company (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020111375-A1 | Anhydro sugar derivatives of indolocarbazoles | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-15 | — | — | US | disclosed |
| US-20020107237-A1 | Topoisomerase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-08 | — | — | US | disclosed |
| WO-2002030941-A2 | TOPOISOMERASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030942-A2 | ANHYDRO SUGAR DERIVATIVES OF INDOLOCARBAZOLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111375-A1 | Anhydro sugar derivatives of indolocarbazoles | TOP1, TOP2A, TOP2B | TOP1 1/4885PRKCA 2715/4885EGFR 4240/4885 |
| US-20030220387-A1 | ANHYDRO SUGAR DERIVATIVES OF INDOLOCARBAZOLES | TOP1, TOP2A, TOP2B | TOP1 1/4885PRKCA 2715/4885EGFR 4240/4885 |
| US-20020107237-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | TOP1 1/4885PRKCA 2480/4885EGFR 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.